TRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedMV
M Ventures
m-ventures.com ↗Activity from announced rounds
Activity in this selectionUnited Kingdom · Oct 23, 2026 · Jan 1, 2026
M Ventures is Merck KGaA’s strategic venture investor in biotechnology, scientific tools, electronics and frontier technology. Explore its recorded Funding activity.
Investment focus
M Ventures is the strategic corporate venture investor of Merck KGaA, Darmstadt, Germany. Its mandate spans drug development, life-science tools, electronics, frontier technology and sustainability. The team combines financial and strategic objectives and works with founders and co-investors to bring scientific and technical developments toward commercial use.
Activity recorded by RoundOS
RoundOS records activity across both sides of that mandate: drug developers Remepy, TwoStep Therapeutics and TRIMTECH; research-tool businesses Lightcast and Vizgen; and optical-interconnect companies Quintessent and Polaris Electro-Optics. These published financing records describe the activity captured here, rather than the firm’s complete portfolio.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $74M 2 disclosed · full round size, not this investor’s share